Paclitaxel Drug-eluting Balloon Catheters in the Treatment of Symptomatic Intracranial Atherosclerotic Stenosis and Restenosis

Stroke Clinical Trial

Official title:

A Prospective, Multicenter, Clinical Trial to Evaluate the Safety and Effectiveness of the Intracranial Paclitaxel Drug-eluting Balloon Catheters (SeQuent® Please CIS) in the Endovascular Treatment of Symptomatic Intracranial Atherosclerotic Stenosis and Restenosis After Interventional Therapy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06047964
• Other study ID #: SPINAS
• Status: Recruiting
• Phase: N/A
• Start date: March 23, 2023
• Est. completion date: January 23, 2025

Study information

• Verified date: September 2023
• Source: B. Braun Medical International Trading Company Ltd.
• Contact: Iris Zhang
• Phone: +86 10 5763 2775
• Email: Iris.zhang[@]bbraun.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is aiming to evaluate the safety and efficacy of SeQuent® Please CIS in the endovascular treatment of symptomatic intracranial atherosclerotic stenosis and restenosis after interventional therapy.

Description:

This study includes 2 sub-studies, sub-study A and sub-study B, namely.

Sub-study A is a prospective, multicenter, randomized controlled, superior clinical trial to evaluate the safety and effectiveness of paclitaxel drug-releasing intracranial balloon catheter (SeQuent® Please CIS) in the treatment of symptomatic intracranial atherosclerotic stenosis.

Sub-study B is a prospective, multicenter, single-arm clinical trial designed to evaluate the safety and efficacy of paclitaxel drug-releasing intracranial balloon catheter (SeQuent® Please CIS) for the treatment of restenosis following interventional treatment for symptomatic intracranial atherosclerotic stenosis.

A total of 277 subjects are expected to be enrolled, including 252 subjects in sub-study A and 25 subjects in sub-study B. Subjects enrolled in sub-study A will be randomized into the study arm and the control arm with the ratio of 1:1. The study arm will be treated with SeQuent® Please CIS (paclitaxel drug-releasing intracranial balloon catheter), while the control arm will be treated with intracranial PTA balloon catheter. Subjects enrolled in sub-study A will all be treated with SeQuent®, Please CIS.

All subjects will be followed up till 12 month post procedure.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 277
• Est. completion date: January 23, 2025
• Est. primary completion date: July 23, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Aged 18 to 80 years old (including boundary value), gender is not limited;

2. The target lesion of the patient is a symptomatic intracranial atherosclerotic stenosis lesion (for part A only) or restenosis lesions after interventional therapy (for part B only);

3. Symptomatic intracranial arterial stenosis (intracranial segment of internal carotid artery (Petrous segment and above), middle cerebral artery, intracranial segment of vertebral artery, basilar artery, etc.) within 6 months, the degree of stenosis of the diseased artery is between 70% and 99% (WASID method);

4. Patients with symptoms occurring more than once (symptoms refer to stroke or transient ischemic attacks) after intensive drug therapy of internal medicine (including antiplatelet therapy, antihypertensive therapy, hypoglycemic therapy and lipid-lowering therapy);

5. The intracranial arterial stenosis lesion to be treated is a single lesion;

6. Patients with at least 1 risk factor for intracranial atherosclerotic plaque, including previous or existing hypertension, hyperlipidemia, diabetes, smoking;

7. Preoperative mRS = 2, and NIHSS=8;

8. Patients whose life expectancy is greater than 12 months as assessed by the investigator.

9. Patients or their guardians can understand the trial purpose, voluntarily participate in and sign the informed consent form, and can accept follow-up visits.

Exclusion Criteria:

1. Severe calcification in the target vessel, severe distortion of the target vessel or anatomical factors that make it hard for interventional devices to be in place;

2. Ischemic symptoms are only associated with branch events;

3. Severe stenosis or occlusion of tandem extracranial or intracranial vessels at the proximal or distal end of the target vessel;

4. Angioplasty or stenting procedures is planned for extracranial vascular lesions with tandem intracranial vessels;

5. History of endarterectomy in the extracranial segment of carotid artery and vertebral artery within 30 days;

6. The target vessel has previously been treated with stenting or angioplasty or other mechanical devices (for Part A only);

7. Acute or subacute intraluminal thrombosis is found in the target vessel;

8. Patients with intracranial stenosis combined with aneurysm, intracranial tumor or intracranial vascular malformation, or intracranial arterial spasm without significant stenosis;

9. Intracranial hemorrhage (cerebral intraparenchymal hemorrhage, massive subarachnoid hemorrhage, and subdural/epidural hemorrhage) within 3 months;

10. There are cardiogenic stroke or risk factors that may contribute to cardioembolism, such as fibrillation, left ventricular thrombosis or myocardial infarction within 6 weeks,;

11. Patients with abnormal coagulation function or bleeding tendency (e.g., international normalized ratio (INR) > 1.5);

12. Patients with known hypersensitivity to iodine contrast medium, paclitaxel, or iopromide;

13. Patients who are participating in clinical trials of other drugs or devices;

14. Other conditions that the investigator deems the patient unsuitable for enrollment.

Related Conditions & MeSH terms

• Constriction, Pathologic
• Stroke

Intervention

Device:
• DCB
Intracranial paclitaxel drug-eluting balloon catheters (SeQuent® Please CIS)
• POBA
Intracranial PTA balloon catheter

Locations

Country	Name	City	State
China	Xuanwu Hospital, Capital Medical University	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
B. Braun Medical International Trading Company Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	restenosis incidence of target lesion	angiographic restenosis measured by WASID ( Warfarin-Aspirin Symptomatic Intracranial Disease) method in core-lab	6 months post-procedure
Secondary	Device success rate	Successful delivery, dilatation and withdraw of the balloon	baseline procedure
Secondary	The changes of Modified Rankin Scale(mRS) score	Scores range from 0 to 6, with higher scores indicating more severe nerve damage; Change of mRS score = mRS score at 6 months (12 months) after surgery - mRS score at baseline	6 and 12 months post-procedure
Secondary	The changes of NIH Stroke Scale(NIHSS) score	Scores range from 0 to 42, with higher scores indicating more severe nerve damage; Change of NIHSS score = NIHSS score at 6 months (12 months) after surgery - NIHSS score at baseline.	6 and 12 months post-procedure
Secondary	Number and incidence (%) of target vessel stroke events (including ischemic or hemorrhagic stroke), transient ischemic attack	Incidence of target vessel stroke events (%) = (number of subjects with target vessel stroke events/total number of subjects) × 100%.; Incidence of transient ischemic attacks (%) = (number of subjects with transient ischemic attacks/total number of subjects) × 100%.	6 and 12 months post-procedure
Secondary	Recurrence incidence of ipsilateral ischemic stroke	Recurrence incidence of ipsilateral ischemic stroke (%) = (number of subjects with recurrent ipsilateral ischemic stroke/total number of subjects) × 100%.	30 days, 6 and 12 months post-procedure